Ochi T, Hakomori S, Fujimoto M, Okamura M, Owaki H, Wakitani S, Shimaoka Y, Hayashida K, Tomita T, Kawamura S
Department of Orthopedic Surgery, Osaka University Medical School, Japan.
J Rheumatol. 1993 Dec;20(12):2038-45.
As reported by us, a new myeloid cell population with an oncofetal membrane marker, dimeric Lex (di-Lex; III3FucV3 FucnLc6), was found in the epiphyseal bone marrow adjacent to the involved joints of patients with severe rheumatoid arthritis (RA). Patients with RA received intradermal (id) injections of di-Lex incorporated in liposome or of high molecular weight glycoprotein, or tumor associated carbohydrate antigen (TCA), containing the same carbohydrate epitope as di-Lex. The epiphyseal myeloid cells were reduced or sometimes eliminated during id injection. In random trials of id injection, observation under clinical and laboratory conditions showed improvement in 63% (17/27) of the patients treated for 6 months with appropriate doses of di-Lex (III3FucnLc4), and in 72% (31/43) of those treated with an identical protocol for TCA. However, id injection with monomeric Lex had no effect.
正如我们所报道的，在重症类风湿性关节炎（RA）患者受累关节附近的骨骺骨髓中发现了一种具有癌胚膜标志物二聚体Lex（di-Lex；III3FucV3 FucnLc6）的新髓样细胞群体。RA患者接受皮内（id）注射包裹在脂质体中的di-Lex或高分子量糖蛋白，或与di-Lex含有相同碳水化合物表位的肿瘤相关碳水化合物抗原（TCA）。皮内注射期间，骨骺髓样细胞减少，有时甚至消失。在皮内注射的随机试验中，临床和实验室条件下的观察表明，用适当剂量的di-Lex（III3FucnLc4）治疗6个月的患者中有63%（17/27）病情改善，用相同方案治疗TCA的患者中有72%（31/43）病情改善。然而，皮内注射单体Lex没有效果。
